Cerebral embolic protection devices are proven to work. However, according to one cardiologist, they are still not consistently reducing stroke rates.

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation. 

The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.

The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use. 

When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.

The company's SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.